Clinical Trial Details

Overview

Research Study Summary

A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Single Lobe Treatment of Severe Emphysema

Purpose

This is a multicenter, prospective, randomized, controlled study designed to evaluate improvement of lung function after treatment with the IBV Valve System as compared to medical management in the control group. The control group will be evaluated in the same manner as the treatment group.

The IBV Valve is a small, umbrella-shaped, one-way valve that is placed inside the airways of one lung. It is used to redirect air from the less healthy to the more healthy parts of the lung. This helps to reduce over-inflation and may improve overall lung function and quality of life for people living with emphysema.

To Learn more

CW ID: 204513
Date Last Changed: January 6, 2015

Clinical Trial Snapshot

Gender
Both Male and Female
Age
40 and up
Overall Status
Recruiting
Lead Sponsor
Spiration, Inc.
Facility Type
N/A

Eligibility

Inclusion Criteria:

  • Subject has severe and heterogeneous emphysema with severe dyspnea
  • Subject certified to meet the criteria of ATS/ERS guidelines for management of stable COPD
  • Subject must be able to demonstrate physical ability to participate in the study by performing a 6-minute walk distance of ≥ 140 m
  • Subject has abstained from cigarette smoking for 4 months and is willing to abstain throughout the study
  • Pulmonary Function Testing Results (PFT's) demonstrate:
    • FEV1 ≤ 45% of predicted
    • RV ≥ 150% of predicted
    • TLC ≥ 100% of predicted

Exclusion Criteria:

  • Patient has a BMI < 15 kg/m2 or > 35 kg/m2
  • Arterial Blood Gas Level (ABG) indicates:
    • PCO2 > 50 mm Hg
    • PO2 < 45 mm Hg on room air
  • Subject has a diffuse emphysema pattern or a1-antitrypsin deficiency
  • Subject has bronchitis with sputum production > 4 Tablespoons or 60 ml per day
  • Subject has an active asthma (>15 mg of prednisone daily)
  • Giant bulla (> 1/3 volume of lung)
  • Pulmonary hypertension
  • Subject with prior major lung surgery or recent hospitalization for COPD exacerbation or respiratory infections

Contact

Brenda Farlow
University of South Florida - Tampa General Hospital
1 Tampa General Circle
Tampa, FL 33606
Phone: (813)844-3430

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.